{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:11:19Z","timestamp":1790161879002,"version":"4.1.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T00:00:00Z","timestamp":1492992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>On May 17, 2016, after an expedited priority review, the U.S. Food and Drug Administration granted accelerated approval to nivolumab for the treatment of patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and post-transplantation brentuximab vedotin (BV). Nivolumab in cHL had been granted breakthrough therapy designation. Accelerated approval was based on two single-arm, multicenter trials in adults with cHL. In 95 patients with relapsed or progressive cHL after autologous HSCT and post-transplantation BV, nivolumab, dosed at 3 mg\/kg intravenously every 2 weeks, produced a 65% (95% confidence interval: 55%\u201375%) objective response rate (58% partial remission, 7% complete remission). The estimated median duration of response was 8.7 months, with 4.6-month median follow-up for response duration. The median time to response was 2.1 (range: 0.7\u20135.7) months. Among 263 patients with cHL treated with nivolumab, 21% reported serious adverse reactions (ARs). The most common all-grade ARs (reported in \u226520%) were fatigue, upper respiratory tract infection, cough, pyrexia, diarrhea, elevated transaminases, and cytopenias. Infusion-related reaction and hypothyroidism or thyroiditis occurred in &amp;gt;10% of patients; other immune-mediated ARs, occurring in 1%\u20135%, included rash, pneumonitis, hepatitis, hyperthyroidism, and colitis. A new Warning and Precaution was issued for complications of allogeneic HSCT after nivolumab, including severe or hyperacute graft-versus-host disease, other immune-mediated ARs, and transplant-related mortality. Continued approval for the cHL indication may be contingent upon verification of clinical benefit in a randomized trial.<\/jats:p>","DOI":"10.1634\/theoncologist.2017-0004","type":"journal-article","created":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T20:55:36Z","timestamp":1493067336000},"page":"585-591","source":"Crossref","is-referenced-by-count":138,"title":["FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma"],"prefix":"10.1093","volume":"22","author":[{"given":"Yvette L.","family":"Kasamon","sequence":"first","affiliation":[{"name":"Office of Hematology and Oncology Products and Office of Biostatistics Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Angelo","family":"de Claro","sequence":"additional","affiliation":[{"name":"Office of Hematology and Oncology Products and Office of Biostatistics Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Wang","sequence":"additional","affiliation":[{"name":"Office of Hematology and Oncology Products and Office of Biostatistics Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan Li","family":"Shen","sequence":"additional","affiliation":[{"name":"Office of Hematology and Oncology Products and Office of Biostatistics Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann T.","family":"Farrell","sequence":"additional","affiliation":[{"name":"Office of Hematology and Oncology Products and Office of Biostatistics Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Pazdur","sequence":"additional","affiliation":[{"name":"Office of Hematology and Oncology Products and Office of Biostatistics Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,4,24]]},"reference":[{"key":"2021122508015200100_onco12100-bib-0001","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1200\/JCO.2001.19.23.4314","article-title":"Long-term results of blood and marrow transplantation for Hodgkin's lymphoma","volume":"19","author":"Akpek","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122508015200100_onco12100-bib-0002","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/blood-2015-10-671826","article-title":"How I treat relapsed classical Hodgkin lymphoma after autologous stem cell transplant","volume":"127","author":"Alinari","year":"2016","journal-title":"Blood"},{"key":"2021122508015200100_onco12100-bib-0003","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.bbmt.2008.08.014","article-title":"Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma","volume":"14","author":"Burroughs","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122508015200100_onco12100-bib-0004","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00277-010-1146-3","article-title":"Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma","volume":"90","author":"Chen","year":"2011","journal-title":"Ann Hematol"},{"key":"2021122508015200100_onco12100-bib-0005","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1158\/1078-0432.CCR-12-1803","article-title":"U.S. Food and Drug Administration approval summary: Brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma","volume":"18","author":"Claro","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021122508015200100_onco12100-bib-0006","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: Implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021122508015200100_onco12100-bib-0007","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2021122508015200100_onco12100-bib-0008","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122508015200100_onco12100-bib-0009","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1182\/blood-2015-02-567453","article-title":"Immune checkpoint blockade in hematologic malignancies","volume":"125","author":"Armand","year":"2015","journal-title":"Blood"},{"key":"2021122508015200100_onco12100-bib-0010"},{"key":"2021122508015200100_onco12100-bib-0011","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: A multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021122508015200100_onco12100-bib-0012","author":"Bristol-Meyers Squibb","year":"2016"},{"key":"2021122508015200100_onco12100-bib-0013","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122508015200100_onco12100-bib-0014","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"key":"2021122508015200100_onco12100-bib-0015","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/blood-2013-05-500801","article-title":"Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality","volume":"122","author":"Saha","year":"2013","journal-title":"Blood"},{"key":"2021122508015200100_onco12100-bib-0016","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"key":"2021122508015200100_onco12100-bib-0017","author":"Timmerman","year":"2016"},{"key":"2021122508015200100_onco12100-bib-0018","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0004","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0004","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/5\/585\/41915963\/oncolo_22_5_585.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/5\/585\/41915963\/oncolo_22_5_585.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T03:02:15Z","timestamp":1640401335000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/22\/5\/585\/6438967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,24]]},"references-count":18,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,4,24]]},"published-print":{"date-parts":[[2017,5,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0004","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,5,1]]},"published":{"date-parts":[[2017,4,24]]}}}